At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 446 enrolled
Drug / intervention
Fluticasone Furoate/Vilanterol +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
In Brief
A Phase 3 clinical trial evaluating Fluticasone Furoate/Vilanterol, Vilanterol, and 1 other intervention for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 446 participants across 72 sites in 6 countries.
Detailed Summary
The purpose of the study is to investigate the effect of fluticasone furoate/vilanterol Inhalation Powder on arterial stiffness compared with placebo and vilanterol over a 24-week treatment period in subjects with COPD and aortic pulse wave velocity of 11.0 m/s or above.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesGermany, Norway, Philippines, South Korea, Thailand, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2011
First PostedApr 2011
Primary CompletionNov 2014
TodayJul 2026
First PostedApr 18, 2011
Enrollment StartMar 4, 2011
Primary CompletionNov 4, 2014
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 15.2 years ago
Interventions
Fluticasone Furoate/Vilanteroldrug
Inhaled corticosteroid/long acting beta-agonist
Vilanteroldrug
Inhaled long acting beta-agonist
Placebodrug
Placebo